Aimmune Therapeutics (NASDAQ:AIMT) had its price objective raised by analysts at Piper Jaffray Companies from $38.00 to $60.00 in a report issued on Tuesday. The firm currently has an “overweight” rating on the biotechnology company’s stock. Piper Jaffray Companies’ target price indicates a potential upside of 65.75% from the stock’s previous close.

Several other equities research analysts have also recently issued reports on AIMT. Credit Suisse Group raised their price objective on shares of Aimmune Therapeutics from $36.00 to $45.00 and gave the stock an “outperform” rating in a research report on Monday, October 23rd. Zacks Investment Research upgraded shares of Aimmune Therapeutics from a “hold” rating to a “buy” rating and set a $34.00 price objective for the company in a research report on Wednesday, November 8th. Roth Capital started coverage on shares of Aimmune Therapeutics in a research report on Monday, November 20th. They set a “buy” rating and a $60.00 price objective for the company. Wedbush restated an “outperform” rating and set a $70.00 price objective (up from $42.00) on shares of Aimmune Therapeutics in a research report on Monday, October 23rd. Finally, BidaskClub cut shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. Two equities research analysts have rated the stock with a sell rating and five have given a buy rating to the company’s stock. Aimmune Therapeutics has a consensus rating of “Hold” and a consensus price target of $53.80.

Shares of Aimmune Therapeutics (NASDAQ AIMT) opened at $36.20 on Tuesday. Aimmune Therapeutics has a 12-month low of $15.97 and a 12-month high of $38.86.

Aimmune Therapeutics (NASDAQ:AIMT) last issued its earnings results on Monday, November 6th. The biotechnology company reported ($0.63) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.72) by $0.09. research analysts forecast that Aimmune Therapeutics will post -2.57 earnings per share for the current fiscal year.

In other Aimmune Therapeutics news, CEO Stephen George Dilly sold 100,000 shares of Aimmune Therapeutics stock in a transaction dated Monday, September 25th. The shares were sold at an average price of $25.01, for a total transaction of $2,501,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Susan E. Barrowcliffe sold 18,390 shares of Aimmune Therapeutics stock in a transaction dated Wednesday, September 6th. The shares were sold at an average price of $22.00, for a total transaction of $404,580.00. Following the sale, the insider now owns 3,223 shares of the company’s stock, valued at $70,906. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 321,470 shares of company stock valued at $8,538,994. 17.59% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently made changes to their positions in the business. SG Americas Securities LLC increased its position in shares of Aimmune Therapeutics by 10.1% during the second quarter. SG Americas Securities LLC now owns 5,451 shares of the biotechnology company’s stock valued at $112,000 after acquiring an additional 499 shares during the last quarter. Teachers Advisors LLC increased its position in shares of Aimmune Therapeutics by 2.6% during the first quarter. Teachers Advisors LLC now owns 44,349 shares of the biotechnology company’s stock valued at $964,000 after acquiring an additional 1,120 shares during the last quarter. Legal & General Group Plc increased its position in shares of Aimmune Therapeutics by 26.6% during the second quarter. Legal & General Group Plc now owns 7,776 shares of the biotechnology company’s stock valued at $160,000 after acquiring an additional 1,634 shares during the last quarter. American International Group Inc. increased its position in shares of Aimmune Therapeutics by 8.1% during the third quarter. American International Group Inc. now owns 23,591 shares of the biotechnology company’s stock valued at $585,000 after acquiring an additional 1,764 shares during the last quarter. Finally, Strs Ohio increased its position in shares of Aimmune Therapeutics by 6.1% during the second quarter. Strs Ohio now owns 34,600 shares of the biotechnology company’s stock valued at $711,000 after acquiring an additional 2,000 shares during the last quarter. Institutional investors and hedge funds own 73.34% of the company’s stock.

WARNING: “Piper Jaffray Companies Increases Aimmune Therapeutics (AIMT) Price Target to $60.00” was published by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this news story can be accessed at https://www.watchlistnews.com/piper-jaffray-companies-increases-aimmune-therapeutics-aimt-price-target-to-60-00/1744860.html.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.